3S Corporation Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: 3S Corporation Pharmaceutical Export Portfolio Dataset — 13 Products, $505.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

3S Corporation — Pharmaceutical Exporter Profile (2026) | 13 Products, $505.4K Trade | TransData Nexus

3S Corporation

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $505.4K Total Trade · DGFT Verified

3S Corporation is an Indian pharmaceutical exporter with a total trade value of $505.4K across 13 products in 4 therapeutic categories. Based on 264 verified export shipments from Indian Customs (DGFT) records, 3S Corporation is the #1 Indian exporter in 1 product including Lomustine. Top exports include Cyclophosphamide ($171.1K), Warfarin ($103.0K), Procarbazine ($39.2K).

3S Corporation — Export Portfolio & Destination Treemap

3S Corporation pharmaceutical export portfolio — 13 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is 3S Corporation? — Company Overview & Market Position

Established in 1999 by Omprakash Mantry, 3S Corporation is a prominent pharmaceutical exporter based in Mumbai, Maharashtra, India. The company specializes in the export and wholesale distribution of a diverse range of pharmaceutical products, including oncology, critical care, diabetes, and heart care medications. Additionally, 3S Corporation deals in antiretroviral drugs, orphan drugs, over-the-counter medications, and vaccines. Operating as a government-recognized export house, the company sources and delivers authentic drugs from over 40 countries, exporting to more than 180 nations worldwide.

The company's registered office is located at A/14 Bonanza Industrial Estate, Ashok Chakravarty Road, Kandivali (East), Mumbai, Maharashtra, 400101, India. 3S Corporation is a privately held entity, with ownership details not publicly disclosed. The company operates under the Corporate Identification Number (CIN) U51909MH2021PTC370327, as per the Ministry of Corporate Affairs, Government of India. While specific revenue figures are not publicly available, the company has demonstrated consistent growth and expansion in its export operations. The workforce comprises approximately 25 full-time employees, many of whom have been with the company for over a decade, reflecting a stable and experienced team.

What Does 3S Corporation Export? — Product Portfolio Analysis

Top Products by Export Value

1Cyclophosphamide

Product Portfolio — Top 13 by Export Value

3S Corporation exports 13 pharmaceutical products across 4 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cyclophosphamide	Oncology	$171.1K	35	0.9%	9
2	Warfarin	Cardiovascular	$103.0K	9	1.4%	8
3	Procarbazine	Advanced Oncology	$39.2K	18	14.9%	2
4	Daunorubicin	Advanced Oncology	$37.5K	15	5.4%	5
5	Mefloquine	Antimalarial & Antiparasitic	$32.4K	6	1.3%	6
6	Carfilzomib	Advanced Oncology	$26.4K	8	2.2%	4
7	Pomalidomide	Advanced Oncology	$23.0K	48	0.5%	6
8	Tofacitinib	Advanced Oncology	$16.1K	51	0.4%	13
9	Vinorelbine	Advanced Oncology	$14.4K	10	0.4%	9
10	Lomustine	Advanced Oncology	$14.0K	29	13.6%	1
11	Carmustine	Advanced Oncology	$11.8K	15	0.1%	8
12	Regorafenib	Advanced Oncology	$10.3K	7	1.0%	4
13	Mitoxantrone	Advanced Oncology	$6.3K	13	0.3%	7

3S Corporation exports 13 pharmaceutical products across 4 therapeutic categories with a total export value of $505.4K. The company is the #1 Indian exporter in 1 product: Lomustine. The top category is Advanced Oncology (39.4% of portfolio), followed by Oncology (33.8%), indicating a concentrated portfolio with the top 5 products accounting for 75.8% of total export value.

3S Corporation — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

3S Corporation operates a centralized warehouse and storage facility in Mumbai, Maharashtra. The facility spans a combined office space of 4,200 square feet and includes multi-temperature storage capabilities to ensure the integrity of pharmaceutical products. The storage areas consist of an ambient room maintained at 15°–25°C and two state-of-the-art cold rooms operating at 2°–8°C, with capacities of 260 and 505 cubic feet, respectively. These cold rooms are equipped with constant temperature monitoring and alarm systems to detect any temperature excursions or refrigeration failures, ensuring compliance with global standards for the storage and distribution of pharmaceutical products.

3Key Leadership

The leadership team at 3S Corporation is headed by Managing Director Piyansh Omprakash Mantry, who has been associated with the company since its inception. Under his guidance, the company has expanded its product range and global reach. Other key executives include Omprakash Shankarlal Mantry, serving as Director, and Bela Desai, who heads the Accounts & Finance department. The marketing team is led by Senior Marketing Manager Jisha Sukumaran and Marketing Manager for Africa & South American Region, Larissa Dsilva. The purchase department is managed by Niwas Jhawar, ensuring efficient procurement processes.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does 3S Corporation Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

3S Corporation's export activities are primarily focused on regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company adheres to the regulatory requirements of these regions, ensuring that all exported pharmaceutical products meet the necessary standards for quality and safety. While specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed, 3S Corporation's compliance with global standards and its WHO-GSDP (Good Storage and Distribution Practices) accreditation indicate a commitment to maintaining high-quality standards in its export operations.

2Emerging Markets

In addition to established markets, 3S Corporation has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's ability to source and deliver authentic pharmaceutical products from over 40 countries has facilitated its expansion into these regions. The WHO-GSDP accreditation further enhances the company's credibility and ability to meet the regulatory requirements of these emerging markets, enabling access to a broader customer base.

3Geographic Strategy

3S Corporation — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding 3S Corporation's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to global standards and its WHO-GSDP accreditation suggest a commitment to maintaining high-quality standards in its export operations. The absence of publicly available FDA-related information indicates that 3S Corporation may not currently hold FDA approvals for its products.

2WHO & EU GMP

3S Corporation holds a WHO-GSDP (Good Storage and Distribution Practices) accreditation, indicating compliance with the World Health Organization's standards for the storage and distribution of pharmaceutical products. This accreditation underscores the company's commitment to maintaining high-quality standards in its export operations. Specific details regarding EU Good Manufacturing Practice (GMP) certificates and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The absence of publicly available information suggests that 3S Corporation may not currently hold EU GMP certifications or EDQM status.

3CDSCO & Indian Regulatory

3S Corporation — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

3S Corporation operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, the company's focus on oncology, critical care, diabetes, and heart care medications positions it in direct competition with other exporters specializing in these therapeutic areas. The company's ability to source and deliver authentic pharmaceutical products from over 40 countries and export to more than 180 nations worldwide enhances its competitive edge. Additionally, the WHO-GSDP accreditation and compliance with global standards for storage and distribution further strengthen its position in the market.

2Key Differentiators

3S Corporation's key differentiators include its extensive network of manufacturers, dealers, wholesalers, and retailers across India, enabling the sourcing of a wide range of pharmaceutical products. The company's specialization in supplying bulk quantities of difficult-to-find drugs and medicines at competitive rates caters to a niche market segment. The focus on branded quality products and the guarantee of 100% genuine and authentic drugs enhance the company's reputation and trustworthiness among clients. The WHO-GSDP accreditation underscores the company's commitment to maintaining high-quality standards in the storage and distribution of pharmaceutical products.

Strategic Position

Buyer Due Diligence Brief — Evaluating 3S Corporation as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

3S Corporation has demonstrated a strong track record in the pharmaceutical export sector, with a total export value of $505,000 USD and 264 shipments across 13 products in four therapeutic categories. The company's portfolio concentration is notable, with the top five products accounting for 75.8% of total exports. The focus on high-demand products such as Cyclophosphamide, Warfarin, Procarbazine, Daunorubicin, and Mefloquine indicates a strategic approach to meeting market needs.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — 3S Corporation

How many pharmaceutical products does 3S Corporation export from India?

3S Corporation exports 13 pharmaceutical products across 4 therapeutic categories. The top exports are Cyclophosphamide ($171.1K), Warfarin ($103.0K), Procarbazine ($39.2K), Daunorubicin ($37.5K), Mefloquine ($32.4K). Total export value is $505.4K.

What is 3S Corporation's total pharmaceutical export value?

3S Corporation's total pharmaceutical export value is $505.4K, based on 264 verified shipments recorded in Indian Customs (DGFT) data.

In which products is 3S Corporation the #1 Indian exporter?

3S Corporation is the #1 Indian exporter in 1 products: Lomustine (13.6% market share).

What therapeutic categories does 3S Corporation cover?

3S Corporation exports across 4 therapeutic categories. The largest are Advanced Oncology (39.4%, 10 products), Oncology (33.8%, 1 products), Cardiovascular (20.4%, 1 products).

Get Full 3S Corporation Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.